Federico Moro

Mr. Federico Moro


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
silvia bordonisilvia bordoni
silvia bordoni
MMMagda Monari
Magda Monari
Carla BogaCarla Boga
Carla Boga
Federico MoroFederico Moro
Federico Moro
GDGiacomo Drius
Giacomo Drius
The use of metal-based species bearing existing pharmaceuticals as ligands, often resulting in enhanced bioactivity, represents an attractive strategy for the development of novel therapeutic formulations. In the context, five well-known non-steroidal anti-inflammatory drugs (NSAIDs) were employed to substitute both PPh₃ and hydride ligands in [Ru(H)₂(CO)(PPh₃)₃] (1), selectively affording, via molecular hydrogen release, neutral κ²-(O,O)-chelate complexes in satisfactory yields. Among the obtained species, two complexes coordinating diclofenac (4) and aspirin (5) were further investigated by single-crystal X-ray diffraction (SCXRD). Preliminary biological studies on the ruthenium-salicylic acid species 2 showed promising antiproliferative activity against HeLa cancer cells, consistent with the fact that NSAID–ruthenium(II) complexes represent a well-established research area for the development of novel anticancer metallotherapeutics.

9 February 2026 in Molecules
Verified
Journal Article
Open access
PDF file
silvia bordonisilvia bordoni
silvia bordoni
MMMagda Monari
Magda Monari
Carla BogaCarla Boga
Carla Boga
Federico MoroFederico Moro
Federico Moro
GDGiacomo Drius
Giacomo Drius
The use of metal-based species bearing existing pharmaceuticals as ligands—often resulting in enhanced bioactivity—represents an attractive strategy for the development of novel therapeutic formulations. In this context, five well-known non-steroidal anti-inflammatory drugs (NSAIDs) were employed to substitute both PPh3 and hydride ligands in [Ru(H)2(CO)(PPh3)3] (1), thereby selectively affording neutral κ2-(O,O)–chelate complexes in satisfactory yields via molecular hydrogen release. Among the obtained species, two complexes coordinating diclofenac (4) and aspirin (5) were further investigated by single-crystal X-ray diffraction (SCXRD). Preliminary biological studies were conducted on the ruthenium–salicylic acid species 2 and ibuprofen 6. The former showed promising antiproliferative activity against HeLa cancer cells, consistent with the well-established role of NSAID–ruthenium(II) complexes as a platform for the development of novel anticancer metallotherapeutics.